An early look at the Organ Procurement and Transplantation Network explant pathology form data

Liver Transplantation

Volumn 22, Issue 6, 2016, Pages 757-764

  Harper, Ann M ^a   Edwards, Erick ^a   Washburn, W Kenneth ^b   Heimbach, Julie ^c  

^a UNITED NETWORK FOR ORGAN SHARING   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN;

ABLATION THERAPY; ADULT; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; EXPLANT; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORGAN PROCUREMENT AND TRANSPLANTATION NETWORK; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT DISEASE; TUMOR DIFFERENTIATION; TUMOR INVASION; TUMOR VOLUME; AGE; CARCINOMA, HEPATOCELLULAR; COHORT ANALYSIS; DIAGNOSTIC IMAGING; EARLY CANCER DIAGNOSIS; EPIDEMIOLOGY; HOSPITAL ADMISSION; LIVER; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; RISK FACTOR; SEX DIFFERENCE; STANDARDS; TIME FACTOR; TRANSPLANTATION; TUMOR RECURRENCE;

AGE FACTORS; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LIVER; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RISK FACTORS; SEX FACTORS; TIME FACTORS; TISSUE AND ORGAN PROCUREMENT; TUMOR BURDEN; WAITING LISTS;

EID: 84970023709     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24441     Document Type: Article

References (21)

1. Kim WR, Stock PG, Smith JM, Heimbach JK, Skeans MA, Edwards EB,. OPTN/SRTR 2011 annual data report: liver. Am J Transplant 2013; 13 (suppl): 73-102.
2. Washburn K, Edwards E, Harper A, Freeman R,. Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system. Am J Transplant 2010; 10: 1643-1648.
3. Based on OPTN data as of July 1, 2014.
4. American Liver Tumor Study Group-A Randomized Prospective Multi-Institutional Trial of Orthotopic Liver Transplantation or Partial Hepatic Resection with or without Adjuvant Chemotherapy for Hepatocellular Carcinoma. Investigators Booklet and Protocol 1998.
5. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al., Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.
6. Llovet JM, Beaugrand M,. Hepatocellular carcinoma: present status and future prospects. J Hepatol 2003; 38 (suppl 1): S136-S149.
7. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al.,; for United Network for Organ Sharing Liver Disease Severity Score Committee. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-96.
8. Organ Procurement and Transplantation Network. http://optn.transplant.hrsa.gov/governance/policies/. Accessed on July 8, 2015.
9. Pomfret EA, Washburn K, Wald C, Nalesnik MA, Douglas D, Russo M, et al., Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010; 16: 262-278.
10. SAS Institute. The LOGISTIC Procedure. SAS/STAT 13.2 User's Guide. Cary, NC: SAS Institute Inc.; 2014.
11. Harper AM. Data presented to the OPTN Liver and Intestinal Organ Transplantation Committee, October 20 2013.
12. Halazun KJ, Patzer RE, Rana AA, Verna EC, Griesemer AD, Parsons RF, et al., Standing the test of time: outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment. Hepatology 2014; 60: 1957-1962.
13. Freeman RB, Mithoefer A, Ruthazer R, Nguyen K, Schore A, Harper A, Edwards E,. Optimizing staging for hepatocellular carcinoma before liver transplantation: A retrospective analysis of the UNOS/OPTN database. Liver Transpl 2006; 12: 1504-1511.
14. Wald C, Russo MW, Heimbach JK, Hussain HK, Pomfret EA, Bruix J,. New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 2013; 266: 376-382.
15. Agopian VG, Harlander-Locke M, Zarrinpar A, Kaldas FM, Farmer DG, Yersiz H, et al., A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients. J Am Coll Surg 2015; 220: 416-427.
16. Chan EY, Larson AM, Fix OK, Yeh MM, Levy AE, Bakthavatsalam R, et al., Identifying risk for recurrent hepatocellular carcinoma after liver transplantation: implications for surveillance studies and new adjuvant therapies. Liver Transpl 2008; 14: 956-965.
17. Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, et al.,; for Liver Transplantation French Study Group. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012; 143: 986-994.
18. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP,. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007; 7: 2587-2596.
19. Onaca N, Davis GL, Goldstein RM, Jennings LW, Klintmalm GB,. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl 2007; 13: 391-399.
20. Guiteau JJ, Cotton RT, Washburn WK, Harper A, O'Mahony CA, Sebastian A, et al., An early regional experience with expansion of Milan criteria for liver transplant recipients. Am J Transplant 2010; 10: 2092-2098.
21. Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, Fix O, et al., Down-staging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology 2015; 61: 1968-1977.